202 related articles for article (PubMed ID: 15486535)
21. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis.
Dhainaut JF; Yan SB; Margolis BD; Lorente JA; Russell JA; Freebairn RC; Spapen HD; Riess H; Basson B; Johnson G; Kinasewitz GT;
Thromb Haemost; 2003 Oct; 90(4):642-53. PubMed ID: 14515185
[TBL] [Abstract][Full Text] [Related]
22. Drotrecogin alfa (activated) for severe sepsis.
Maglio D
Conn Med; 2002 Mar; 66(3):145-50. PubMed ID: 11957766
[No Abstract] [Full Text] [Related]
23. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis.
Scipione MR; Nogid B; Davanos E; DiGregorio RV
Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886
[TBL] [Abstract][Full Text] [Related]
24. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
25. Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy.
Sollet JP; Garber GE
Am J Surg; 2002 Dec; 184(6A Suppl):S11-8. PubMed ID: 12521613
[TBL] [Abstract][Full Text] [Related]
26. Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?
Friedrich JO; Adhikari NK; Meade MO
Crit Care; 2006; 10(3):145. PubMed ID: 16762040
[TBL] [Abstract][Full Text] [Related]
27. Activated protein C and septic shock: a propensity-matched cohort study*.
Rimmer E; Kumar A; Doucette S; Marshall J; Dial S; Gurka D; Dellinger RP; Sharma S; Penner C; Kramer A; Wood K; Ronald J; Kumar A; Turgeon AF; Houston DS; Zarychanski R;
Crit Care Med; 2012 Nov; 40(11):2974-81. PubMed ID: 22932397
[TBL] [Abstract][Full Text] [Related]
28. Clinical and laboratory effects of recombinant human activated protein C in the treatment of a patient with sepsis-induced multiple organ failure.
Brueckmann M; Wizenmann J; Hoffmann U; Seeger M; Bewig B
Thromb Res; 2003 Mar; 109(5-6):259-63. PubMed ID: 12818248
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.
Angus DC; Linde-Zwirble WT; Clermont G; Ball DE; Basson BR; Ely EW; Laterre PF; Vincent JL; Bernard G; van Hout B;
Crit Care Med; 2003 Jan; 31(1):1-11. PubMed ID: 12544986
[TBL] [Abstract][Full Text] [Related]
30. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis.
Barie PS; Williams MD; McCollam JS; Bates BM; Qualy RL; Lowry SF; Fry DE;
Am J Surg; 2004 Sep; 188(3):212-20. PubMed ID: 15450822
[TBL] [Abstract][Full Text] [Related]
31. Activated recombinant protein C in septic shock early after liver transplantation: a case report.
Feltracco P; Bortolato A; Rizzi S; Barbieri S; Furnari M; Serra E; Milevoj M; Ori C
Transplant Proc; 2008; 40(6):2070-2. PubMed ID: 18675133
[TBL] [Abstract][Full Text] [Related]
32. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C.
Yan SB; Nelson DR
Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525
[TBL] [Abstract][Full Text] [Related]
33. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
34. A novel use for drotrecogin alfa (activated): successful treatment of septic shock associated with coccidioidomycosis.
Crum NF; Groff HL; Parrish JS; Ring W
Clin Infect Dis; 2004 Dec; 39(11):e122-3. PubMed ID: 15578351
[TBL] [Abstract][Full Text] [Related]
35. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
36. Management challenge with drotrecogin alfa (activated).
Vanscoy GJ
Am J Health Syst Pharm; 2002 Feb; 59 Suppl 1():S23-9. PubMed ID: 11885411
[TBL] [Abstract][Full Text] [Related]
37. Drotrecogin alfa (activated) in the treatment of severe sepsis.
Vincent JL
Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934
[TBL] [Abstract][Full Text] [Related]
38. Introduction: rationale for using drotrecogin alfa (activated) in patients with severe sepsis.
Dhainaut JF
Am J Surg; 2002 Dec; 184(6A Suppl):S5-10. PubMed ID: 12521612
[No Abstract] [Full Text] [Related]
39. New and emerging therapies for sepsis.
Healy DP
Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
[TBL] [Abstract][Full Text] [Related]
40. [Focal surgery, antibiotic therapy--and then? The role of rhAPC in sepsis].
Spies C; Otter H; Zuckermann-Becker H; Kox WJ
Kongressbd Dtsch Ges Chir Kongr; 2002; 119():834-43. PubMed ID: 12704933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
